Differential patterns of blood oxygenation in the prefrontal cortex between patients with methamphetamine-induced psychosis and schizophrenia

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yamamuro, Kazuhiko ^a   Makinodan, Manabu ^a   Kimoto, Sohei ^a   Kishimoto, Naoko ^a   Morimoto, Tsubasa ^a   Toritsuka, Michihiro ^a   Matsuoka, Kiwamu ^a   Takebayashi, Yoshihiro ^a   Takata, Tomoyo ^a   Takahashi, Masato ^a   Tanimura, Yoshinori ^a   Nishihata, Yosuke ^a   Matsuda, Yasuhiro ^a   Ota, Toyosaku ^a   Yoshino, Hiroki ^a   Iida, Junzo ^a   Kishimoto, Toshifumi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHAMPHETAMINE; OXYGEN;

ADULT; BLOOD; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SPEECH;

ADULT; FEMALE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; OXYGEN; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SPEECH;

EID: 84937509274     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12107     Document Type: Article

References (49)

1. Kishimoto, M. et al. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biological psychiatry 63, 191-196, doi: 10.1016/j.biopsych.2007.03.019 (2008).
2. Matsuzawa, D. et al. Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. The American journal of psychiatry 164, 1105-1114, doi: 10.1176/appi. ajp.164.7.1105 (2007).
3. Farrell, M., Marsden, J., Ali, R. & Ling, W. Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction (Abingdon, England) 97, 771-772 (2002).
4. McKetin, R., McLaren, J., Lubman, D. I. & Hides, L. The prevalence of psychotic symptoms among methamphetamine users. Addiction (Abingdon, England) 101, 1473-1478, doi: 10.1111/j.1360-0443.2006.01496.x (2006).
5. Mahoney, J. J., 3rd, Kalechstein, A. D., De La Garza, R., 2nd & Newton, T. F. Presence and persistence of psychotic symptoms in cocaine-versus methamphetamine-dependent participants. The American journal on addictions/American Academy of Psychiatrists in Alcoholism and Addictions 17, 83-98, doi: 10.1080/10550490701861201 (2008).
6. Batki, S. L. & Harris, D. S. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. The American journal on addictions/American Academy of Psychiatrists in Alcoholism and Addictions 13, 461-470, doi: 10.1080/10550490490512834 (2004).
7. Curran, C., Byrappa, N. & McBride, A. Stimulant psychosis: systematic review. The British journal of psychiatry : the journal of mental science 185, 196-204, doi: 10.1192/bjp.185.3.196 (2004).
8. Sato, M., Numachi, Y. & Hamamura, T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophrenia bulletin 18, 115-122 (1992).
9. Snyder, S. H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. The American journal of psychiatry 130, 61-67 (1973).
10. Weich, L. & Pienaar, W. Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa. African journal of psychiatry 12, 213-217 (2009).
11. Srisurapanont, M. et al. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Progress in neuro-psychopharmacology & biological psychiatry 35, 959-964, doi: 10.1016/j.pnpbp.2011.01.014 (2011).
12. Srisurapanont, M. et al. Psychotic symptoms in methamphetamine psychotic in-patients. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 6, 347-352, doi: 10.1017/s1461145703003675 (2003).
13. Tomiyama, G. Chronic schizophrenia-like states in methamphetamine psychosis. The Japanese journal of psychiatry and neurology 44, 531-539 (1990).
14. Green, M. F. What are the functional consequences of neurocognitive deficits in schizophrenia? The American journal of psychiatry 153, 321-330, doi: 10.1176/ajp.153.3.321 (1996).
15. Horan, W. P. et al. Impaired implicit learning in schizophrenia. Neuropsychology 22, 606-617, doi: 10.1037/a0012602 (2008).
16. Mueser, K. T. & McGurk, S. R. Schizophrenia. Lancet 363, 2063-2072, doi: 10.1016/s0140-6736(04)16458-1 (2004).
17. Kahn, R. S. & Keefe, R. S. Schizophrenia is a cognitive illness: time for a change in focus. JAMA psychiatry 70, 1107-1112, doi: 10.1001/jamapsychiatry.2013.155 (2013).
18. Jacobs, E., Fujii, D., Schiffman, J. & Bello, I. An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia. Cognitive and behavioral neurology:official journal of the Society for Behavioral and Cognitive Neurology 21, 98-103, doi: 10.1097/WNN.0b013e31816bdf90 (2008).
19. Scott, J. C. et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychology review 17, 275-297, doi: 10.1007/s11065-007-9031-0 (2007).
20. Bramness, J. G. et al. Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC psychiatry 12, 221, doi: 10.1186/1471-244x-12-221 (2012).
21. Medhus, S., Mordal, J., Holm, B., Morland, J. & Bramness, J. G. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry research 206, 17-21, doi: 10.1016/j.psychres.2012.09.023 (2013).
22. Smith, J. L., Mattick, R. P., Jamadar, S. D. & Iredale, J. M. Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis. Drug and alcohol dependence 145, 1-33, doi: 10.1016/j.drugalcdep.2014.08.009 (2014).
23. Hughes, M. E., Fulham, W. R., Johnston, P. J. & Michie, P. T. Stop-signal response inhibition in schizophrenia: behavioural, event-related potential and functional neuroimaging data. Biological psychology 89, 220-231, doi: 10.1016/j.biopsycho.2011.10.013 (2012).
24. Callaghan, R. C. et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. The American journal of psychiatry 169, 389-396, doi: 10.1176/appi.ajp.2011.10070937 (2012).
25. Rounsaville, B. J. DSM-V research agenda: substance abuse/psychosis comorbidity. Schizophrenia bulletin 33, 947-952, doi: 10.1093/schbul/sbm054 (2007).
26. Okada, N. et al. Characterizing prefrontal cortical activity during inhibition task in methamphetamine-associated psychosis versus schizophrenia: a multi-channel near-infrared spectroscopy study. Addiction biology, doi: 10.1111/adb.12224 (2015).
27. Koike, S. et al. Different hemodynamic response patterns in the prefrontal cortical sub-regions according to the clinical stages of psychosis. Schizophrenia research 132, 54-61, doi: 10.1016/j.schres.2011.07.014 (2011).
28. Takizawa, R. et al. Reduced frontopolar activation during verbal fluency task in schizophrenia: a multi-channel near-infrared spectroscopy study. Schizophrenia research 99, 250-262, doi: 10.1016/j.schres.2007.10.025 (2008).
29. Tsujimoto, S., Genovesio, A. & Wise, S. P. Frontal pole cortex: encoding ends at the end of the endbrain. Trends in cognitive sciences 15, 169-176, doi: 10.1016/j.tics.2011.02.001 (2011).
30. Yang, Y., Raine, A., Colletti, P., Toga, A. W. & Narr, K. L. Abnormal temporal and prefrontal cortical gray matter thinning in psychopaths. Molecular psychiatry 14, 561-562, 555, doi: 10.1038/mp.2009.12 (2009).
31. Crockett, M. J. et al. Restricting temptations: neural mechanisms of precommitment. Neuron 79, 391-401, doi: 10.1016/j. neuron.2013.05.028 (2013).
32. Broome, M. R. et al. Neural correlates of executive function and working memory in the 'at-risk mental state'. The British journal of psychiatry : the journal of mental science 194, 25-33, doi: 10.1192/bjp.bp.107.046789 (2009).
33. Henry, J. D. & Crawford, J. R. A meta-analytic review of verbal fluency performance following focal cortical lesions. Neuropsychology 18, 284-295, doi: 10.1037/0894-4105.18.2.284 (2004).
34. Curtis, V. A. et al. Attenuated frontal activation during a verbal fluency task in patients with schizophrenia. The American journal of psychiatry 155, 1056-1063 (1998).
35. Lewis, R. Should cognitive deficit be a diagnostic criterion for schizophrenia? Journal of psychiatry & neuroscience : JPN 29, 102-113 (2004).
36. Kang, S. S., Sponheim, S. R., Chafee, M. V. & MacDonald, A. W., 3rd. Disrupted functional connectivity for controlled visual processing as a basis for impaired spatial working memory in schizophrenia. Neuropsychologia 49, 2836-2847, doi: 10.1016/j. neuropsychologia.2011.06.009 (2011).
37. Van Veelen, N. M., Vink, M., Ramsey, N. F. & Kahn, R. S. Left dorsolateral prefrontal cortex dysfunction in medication-naive schizophrenia. Schizophrenia research 123, 22-29, doi: 10.1016/j.schres.2010.07.004 (2010).
38. Chen, C. K. et al. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug and alcohol dependence 148, 158-164, doi: 10.1016/j.drugalcdep.2014.12.035 (2015).
39. Oldfield, R. C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9, 97-113 (1971).
40. Matsuoka, K., Uno, M., Kasai, K., Koyama, K. & Kim, Y. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. Psychiatry and clinical neurosciences 60, 332-339, doi: 10.1111/j.1440-1819.2006.01510.x (2006).
41. Keefe, R. S. et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia research 68, 283-297, doi: 10.1016/j.schres.2003.09.011 (2004).
42. Keefe, R. S., Poe, M., Walker, T. M., Kang, J. W. & Harvey, P. D. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. The American journal of psychiatry 163, 426-432, doi: 10.1176/appi.ajp.163.3.426 (2006).
43. Keefe, R. S. et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia research 102, 108-115, doi: 10.1016/j.schres.2008.03.024 (2008).
44. Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin 13, 261-276 (1987).
45. Sawamura, J., Morishita, S. & Ishigooka, J. Is there a linear relationship between the Brief Psychiatric Rating Scale and the Clinical Global Impression-Schizophrenia scale? A retrospective analysis. BMC psychiatry 10, 105, doi: 10.1186/1471-244x-10-105 (2010).
46. Hoshi, Y., Kobayashi, N. & Tamura, M. Interpretation of near-infrared spectroscopy signals: a study with a newly developed perfused rat brain model. Journal of applied physiology (Bethesda, Md. : 1985) 90, 1657-1662 (2001).
47. Schweitzer, J. B. et al. Alterations in the functional anatomy of working memory in adult attention deficit hyperactivity disorder. The American journal of psychiatry 157, 278-280 (2000).
48. Toronov, V. et al. Investigation of human brain hemodynamics by simultaneous near-infrared spectroscopy and functional magnetic resonance imaging. Medical physics 28, 521-527 (2001).
49. Singh, A. K. & Dan, I. Exploring the false discovery rate in multichannel NIRS. NeuroImage 33, 542-549, doi: 10.1016/j. neuroimage.2006.06.047 (2006).